Entero Therapeutics (NASDAQ:GRDX) Lowered to Strong Sell Rating by Wall Street Zen

Wall Street Zen cut shares of Entero Therapeutics (NASDAQ:GRDX) from a hold rating to a strong sell rating in a report published on Saturday.

Entero Therapeutics Trading Down 1.2%

GRDX stock opened at $3.96 on Friday. The company has a market cap of $28.23 million, a price-to-earnings ratio of -2.08 and a beta of 1.86. Entero Therapeutics has a 12 month low of $1.87 and a 12 month high of $6.93. The firm has a 50-day moving average of $3.76 and a two-hundred day moving average of $3.42.

Entero Therapeutics (NASDAQ:GRDX) last released its earnings results on Wednesday, May 27th. The company reported ($0.82) earnings per share for the quarter. The business had revenue of $0.04 million for the quarter.

Hedge Funds Weigh In On Entero Therapeutics

A hedge fund recently bought a new stake in Entero Therapeutics stock. DRW Securities LLC acquired a new position in shares of Entero Therapeutics, Inc. (NASDAQ:GRDX) during the fourth quarter, according to the company in its most recent Form 13F filing with the Securities and Exchange Commission (SEC). The fund acquired 48,623 shares of the company’s stock, valued at approximately $227,000. DRW Securities LLC owned about 1.45% of Entero Therapeutics as of its most recent filing with the Securities and Exchange Commission (SEC). 12.30% of the stock is owned by hedge funds and other institutional investors.

About Entero Therapeutics

Entero Therapeutics, Inc, a clinical-stage biopharmaceutical company, engages in the development of targeted and orally delivered therapies for the treatment of patients with gastrointestinal diseases. The company’s pipeline candidates include latiglutenase, a targeted oral biotherapeutic for celiac disease designed to breakdown gluten into non-immunogenic peptides, currently under Phase 2 studies; and capeserod, a selective 5-HT4 receptor partial agonist under Phase 1 studies for the treatment of gastroparesis.